Kenvue Inc. (NYSE:KVUE) to Post Q4 2024 Earnings of $0.30 Per Share, William Blair Forecasts

Kenvue Inc. (NYSE:KVUE) – Analysts at William Blair increased their Q4 2024 earnings per share estimates for shares of Kenvue in a report released on Tuesday, June 25th. William Blair analyst J. Andersen now anticipates that the company will earn $0.30 per share for the quarter, up from their previous estimate of $0.29. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Kenvue’s current full-year earnings is $1.17 per share.

Other equities analysts also recently issued reports about the stock. Sanford C. Bernstein started coverage on shares of Kenvue in a research note on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price target on the stock. HSBC raised their price target on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a research note on Wednesday, May 8th. The Goldman Sachs Group started coverage on Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 price target for the company. Finally, Citigroup restated a “neutral” rating and issued a $21.00 price objective on shares of Kenvue in a report on Tuesday, May 28th. One analyst has rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and an average price target of $23.09.

Kenvue Stock Performance

KVUE opened at $18.42 on Thursday. The business has a fifty day simple moving average of $19.22 and a 200-day simple moving average of $20.00. The firm has a market cap of $35.27 billion and a PE ratio of 23.62. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.66. Kenvue has a fifty-two week low of $17.75 and a fifty-two week high of $26.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.03. The company had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $3.79 billion. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm’s revenue for the quarter was down 24.9% on a year-over-year basis.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC grew its holdings in Kenvue by 78.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,155 shares of the company’s stock worth $89,000 after acquiring an additional 1,829 shares during the period. Pathway Financial Advisers LLC acquired a new stake in shares of Kenvue during the first quarter worth $98,000. Soltis Investment Advisors LLC grew its stake in shares of Kenvue by 7.5% during the first quarter. Soltis Investment Advisors LLC now owns 141,581 shares of the company’s stock worth $3,038,000 after purchasing an additional 9,869 shares during the period. Cetera Advisors LLC increased its holdings in Kenvue by 202.0% in the first quarter. Cetera Advisors LLC now owns 212,097 shares of the company’s stock valued at $4,552,000 after purchasing an additional 141,858 shares during the last quarter. Finally, Cetera Investment Advisers lifted its stake in Kenvue by 183.9% in the first quarter. Cetera Investment Advisers now owns 449,506 shares of the company’s stock valued at $9,646,000 after buying an additional 291,179 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th were issued a $0.20 dividend. The ex-dividend date was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.34%. Kenvue’s dividend payout ratio is 102.56%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.